FDA approves Amneal’s self-administered migraine drug Brekiya
Brekiya is now the first DHE auto-injector to be approved by the regulator
Read More
Tag: migraine
NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks
The final draft guidance recommends rimegepant for adults who have at least four migraine attacks per month, but less than 15
Read More
NHS in Scotland receives Pfizer’s migraine treatment
Patients living with the debilitating impacts of migraine attacks will be able to access Vydura
Read More
AbbVie reveals results from pivotal atogepant trial
Study has been focusing on atogepant for the prevention of episodic migraine attacks
Read More
NICE u-turn on Novartis’ migraine drug Aimovig
New analyses submitted by Novartis has helped to secure a NICE recommendation for NHS funding
Read More
NICE recommends Lilly’s migraine med Emgality
CGRP antagonist approved to prevent migraine in adults with episodic and chronic migraine
Read More
UK launch for Ajovy injector pen
Teva’s new device allows migraine sufferers to self-administer the drug
Read More
NICE publishes final guidance backing Teva’s Ajovy for migraine
One in seven UK adults is affected by migraine
Read More
New data back long-term use of Novartis’ Aimovig in migraine
The data add to real world and long-term evidence showing efficacy of Aimovig for migraine prevention across the migraine spectrum
Read More
Ajovy bags NICE approval
The anti-CGRP preventive therapy is the first of-its-kind to be recommended by NICE.
Read More
Late-stage success for experimental migraine drug
The results support the filing of a New Drug Application (NDA) for Axsome’s AXS-07 in the acute treatment of migraine.
Read More
FDA ‘yes’ for Eli Lilly’s Reyvow
The approval marks the first new class of acute migraine treatment approved by the FDA in more than two decades.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
